3D-Conformal Radiation vs Helical Tomotherapy in Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Randomized Phase III Trial of 3D Conformal Radiotherapy Versus Helical Tomotherapy IMRT in High-Risk Prostate Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00326638
• Other study ID #: 2005242-01H
• Secondary ID: OTT 05-02
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 2005
• Est. completion date: June 30, 2020

Study information

• Verified date: April 2020
• Source: Ottawa Hospital Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study we are comparing two forms of radiotherapy. This study is being done because it is not clear at present time whether intensity modulated radiotherapy (IMRT) can reduce side effects of radiotherapy compared to standard radiotherapy (called 3D-Conformal Radiotherapy).

Description:

Radical radiation therapy plays an important role in the management of prostate cancer, yielding comparable long-term outcomes to surgery. Unfortunately, long term disease free survival data using PSA criteria have shown that less than 50% of high-risk patients are free of disease at 10 years. To improve on the results of conventional dose radiotherapy dose escalation with three-dimensional conformal radiation has been employed. Due to the irregular shape of the prostate and the variable motion of this organ there is substantial radiation of adjacent normal surrounding tissue during treatment which results in radiation-induced toxicity. Intensity-modulated radiation therapy (IMRT) is a new form of radiation therapy. Preliminary evidence suggests that IMRT improves the dose distribution during radiation therapy of the prostate. The hypothesis of this study is that IMRT delivered using Helical Tomotherapy can reduce late toxicity of radical radiotherapy as compared to three-dimensional conformal radiation (3DCRT) in high-risk prostate cancer patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 72
• Est. completion date: June 30, 2020
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. A pathologic diagnosis of adenocarcinoma of the prostate

2. Age greater than 18 years

3. ECOG performance status of 2 or less.

4. Presence of any of the following high risk features:

• Clinical stage cT3-4 or

• Gleason score 8-10 or

• Pre-treatment PSA > 20ng/ml or

• Clinical N1/N2 or pathologic N1/N2

Exclusion Criteria:

1. Patients with contraindication to radical radiation therapy including inflammatory bowel disease

2. Prior or active malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer

3. Prior pelvic radiotherapy for other malignancies

4. Prior cytotoxic chemotherapy

5. Prior orchiectomy, radical prostatectomy, cryotherapy or thermal ablation therapy for prostate cancer

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Radiation:
• Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy
IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23 Boost IMRT to Prostate 3,200 cGy/16

Other:
• Arm A: 3D-Conformal Radiation
3DCRT 7800 cGY/39 Fractions/ STD Technique* once daily Monday to Friday for 8 weeks Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23 Boost 6 F 3DCRT to Prostate 3,200 cGy/16

Locations

Country	Name	City	State
Canada	The Ottawa Hospital Regional Cancer Centre	Ottawa	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Late rectal toxicity from radiotherapy of the prostate	Outcome measurements will be determined by physical exam and bloodwork.	Month 1, 4, 8, every 4 months during year 1-2, then every 6 months during years 2-5, then every 12 months until disease progression
Secondary	Acute rectal toxicity, Acute and late bladder toxicity, Disease specific survival at 5 years, Biochemical relapse free survival at 5 years, Local control rates at 5 years, Quality of Life	Outcome measurements will be determined by physical exam and bloodwork.	Month 1, 4, 8, every 4 months during year 1-2, then every 6 months during years 2-5, then every 12 months until disease progression